Xlumena, a Mountain View, California-based provider of innovative technology for the interventional endoscopist and endoscopic surgeon, has closed a $7m Series B financing.
The round was led by new investor Aperture Venture Partners, LLC, with participation from Western Technology Investment and existing backers Prism Ventures, Charter Life Sciences and Ascent Biomedical Ventures.
The company has raised raised $19m from to date.
In conjunction with the financing, Eric Sillman of Aperture Venture Partners and Avi Kometz, MD of Ascent Biomedical Ventures, will join Xlumena’s Board of Directors.
As stated by Michael Allen, President and CEO of Xlumena, the financing will support the company’s market expansion in the US and Europe.
Founded in 2008 by Kenneth Binmoeller, MD, and Allen, Xlumena has a number of advanced therapeutic devices in various stages of development, including the NAVIX™ Access Device (FDA-cleared) and the AXIOS™ Stent and Delivery System (CE marked).